Erica Shenoy

Erica Shenoy


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
KBKimberly G. Blumenthal
Kimberly G. Blumenthal
EFEsther E. Freeman
Esther E. Freeman
RSRebecca R. Saff
Rebecca R. Saff
LRLacey B. Robinson
Lacey B. Robinson
AWAnna R. Wolfson
Anna R. Wolfson
ESErica Shenoy
Erica Shenoy
Baden et al.1 report on a phase 3 clinical trial of the mRNA-1273 vaccine against SARS-CoV-2, and they provide information on immediate injection-site reactions, which were observed in 84.2% of the participants after the first dose. The trial also showed that delayed injection-site reactions (defined in that trial as those with an onset on or after day 8) occurred in 244 of the 30,420 participants (0.8%) after the first dose and in 68 participants (0.2%) after the second dose. These reactions included erythema, induration, and tenderness. The reactions typically resolved over the following 4 to 5 days. However, these reactions were not further characterized, and links between reactions after the first dose and those after the second dose were not provided to inform clinical care.

21 May 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MKMichael Klompas
Michael Klompas
CMCharles A. Morris
Charles A. Morris
JSJulia Sinclair
Julia Sinclair
MPMadelyn Pearson
Madelyn Pearson
ESErica Shenoy
Erica Shenoy
As the SARS-CoV-2 pandemic continues to explode, hospital systems are scrambling to intensify their measures for protecting patients and health care workers from the virus. An increasing number of frontline providers are wondering whether this effort should include universal use of masks by all health care workers. Universal masking is already standard practice in Hong Kong, Singapore, and other parts of Asia and has recently been adopted by a handful of U.S. hospitals.

27 July 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
WMWilfredo R Matias
Wilfredo R Matias
JKJacob M Koshy
Jacob M Koshy
ENEllen H Nagami
Ellen H Nagami
VKVictor Kovac
Victor Kovac
LMLetumile R Moeng
Letumile R Moeng
JLJacob E Lazarus
Jacob E Lazarus
A large, ongoing multicountry outbreak of human monkeypox has the potential to cause considerable morbidity and mortality. Therapeutics for the treatment of smallpox, a related Orthopoxvirus, may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan-Orthopoxvirus inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.

9 June 2022 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
KZKimon C. Zachary
Kimon C. Zachary
ESErica Shenoy
Erica Shenoy
Transmission risk of monkeypox in healthcare settings outside endemic regions has not been well defined. A rapid review of the literature, including cases outside monkeypox-endemic regions from 2000 to 2022 identified a single reported case of transmission. Available literature is limited by nonstandardized exposure definitions and limited detail describing exposures.

11 August 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NBNesli Basgoz
Nesli Basgoz
CBCatherine M Brown
Catherine M Brown
SSSandra C Smole
Sandra C Smole
LMLawrence C Madoff
Lawrence C Madoff
PBPaul D Biddinger
Paul D Biddinger
ESErica Shenoy
Erica Shenoy
Dr. Vivian De Oliveira Rodrigues Gama (Medicine): A 31-year-old man was admitted to this hospital because of perianal and penile ulcers, rectal pain, and vesiculopustular rash.

10 February 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
ESErica Shenoy
Erica Shenoy
WBWestyn Branch-Elliman
Westyn Branch-Elliman
Infection surveillance is one of the cornerstones of infection prevention and control. Measurement of process metrics and clinical outcomes, such as detection of healthcare-associated infections (HAIs), can be used to support continuous quality improvement. HAI metrics are reported as part of the CMS Hospital-Acquired Conditions Program, and they influence facility reputation and financial outcomes.